A Single Dose, Open Label, Randomized, Two-period Cross Over Study in Healthy Male Subjects to Assess the Absolute Bioavailability of YM178 OCAS-M Formulation

Trial Profile

A Single Dose, Open Label, Randomized, Two-period Cross Over Study in Healthy Male Subjects to Assess the Absolute Bioavailability of YM178 OCAS-M Formulation

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jun 2013

At a glance

  • Drugs Mirabegron (Primary) ; Mirabegron (Primary)
  • Indications Overactive bladder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Sep 2012 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
    • 28 Nov 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top